Monday, June 28, 2021

Identification of an Optimal Population for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Mature T and NK Cell Neoplasms

xlomafota13 shared this article with you from Inoreader

In Vivo. 2021 Jul-Aug;35(4):2379-2390. doi: 10.21873/invivo.12515.

ABSTRACT

BACKGROUND/AIM: The prognosis of mature T and natural killer (NK) cell neoplasms still remains dismal, despite the advancements in the understanding of the heterogeneous features of these diseases. As allogeneic stem cell transplantation (alloSCT) is an attractive salvage option for relapsed/refractory patients, we conducted this study to identify those who might benefit the most from alloSCT.

PATIENTS AND METHODS: This was a retrospective, single-center, longitudinal cohort study of patients who received alloSCT between December 2019 and January 2000.

RESULTS: The median relapse-free survival and overall survival were 4.4 and 10.0 months, respectively. Disease control status at alloSCT and number of previous treatments were associated with survival outcomes. The conditioning intensity did not significantly alter survival.

CONCLUSION: AlloSCT offers a cure chance for selected relapsed or refractory T and NK cell neoplasms, especially when used early and the disease is well controlled prior to transplantation.

PMID:34182521 | DOI:10.21873/invivo.12515

View on the web

No comments:

Post a Comment

Collaboration request

Hi there How would you like to earn a 35% commission for each sale for life by selling SEO services Every website owner requires the ...